Corvus Pharmaceuticals (CRVS) Interest & Investment Income (2015 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Interest & Investment Income came in at $1.8 million in Q1 2026, up 239.81% year-on-year from $525000.0 in Q1 2025, and up 141.73% quarter-over-quarter from $738000.0 in Q3 2025.
Corvus Pharmaceuticals (CRVS) Interest & Investment Income (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Interest & Investment Income history runs 12 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 239.81% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 100.22% increase from a year earlier, with the FY2023 full-year figure at $1.6 million, up 142.2% from the prior year.
- Interest & Investment Income grew to $1.8 million in Q1 2026 per CRVS's latest filing, from $738000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.8 million in Q1 2026 and bottomed at $11000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $403000.0 (2023), against an average of $482666.7.
- Across the five-year window, Interest & Investment Income surged 9900.0% in 2022 and retreated 15.96% in 2024, its largest moves.
- Year by year, Interest & Investment Income stood at $318000.0 in 2022, then gained by 19.5% to $380000.0 in 2023, then soared by 48.95% to $566000.0 in 2024, then surged by 30.39% to $738000.0 in 2025, then jumped by 141.73% to $1.8 million in 2026.
- Per Business Quant, the three latest CRVS Interest & Investment Income figures stand at $1.8 million (Q1 2026), $738000.0 (Q3 2025), and $639000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Corvus Pharmaceuticals | 1.17 Bn | 934.14 Mn | - | 1.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.78 Mn |
| Sep 30, 2025 | 738,000.00 |
| Jun 30, 2025 | 639,000.00 |
| Mar 31, 2025 | 525,000.00 |
| Sep 30, 2024 | 566,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Mar 31, 2024 | 316,000.00 |
| Dec 31, 2023 | 380,000.00 |
| Sep 30, 2023 | 425,000.00 |
| Jun 30, 2023 | 403,000.00 |
| Mar 31, 2023 | 376,000.00 |
| Dec 31, 2022 | 318,000.00 |
| Sep 30, 2022 | 225,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 11,000.00 |
| Dec 31, 2021 | -8,000.00 |
| Sep 30, 2021 | -11,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 1,000.00 |